Hansa Biopharma AB (publ) (STO:HNSA)

Sweden · Delayed Price · Currency is SEK

34.48

+2.24 (6.95%)

Jun 12, 2026, 5:29 PM CET

Revenue by Segment

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
Research and Development for Production of Pharmaceuticals	222.27M	171.32M	134.09M	154.53M	33.88M
Research and Development for Production of Pharmaceuticals Growth	29.74%	27.76%	-13.22%	356.12%	455.56%
Total	222.27M	171.32M	134.09M	154.53M	33.88M
Total Growth	29.74%	27.76%	-13.22%	356.12%	455.56%

Revenue by Geography

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
Sweden	-	3.12M	-	4.68M	-
North America	14.09M	27.96M	27.42M	64.27M	15.71M
North America Growth	-49.62%	1.97%	-57.34%	309.12%	-
Europe (Ex Sweden)	202.28M	140.24M	106.68M	85.57M	18.17M
Europe (Ex Sweden) Growth	44.24%	31.46%	24.66%	371.01%	-
Rest of The World	5.90M	-	-	-	-
Total	222.27M	171.32M	134.09M	154.52M	33.88M
Total Growth	29.74%	27.76%	-13.22%	356.12%	455.56%